PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, exploratory, single dose, randomized, double-blind, two-way cross over,
pilot, glucose clamp study to assess pharmacokinetic and pharmacodynamic effects of Gan &
Lee's insulin glargine injection in comparison to the marketed Lantus (US) in subjects with
type 1 diabetes mellitus (T1DM).
Phase:
Phase 1
Details
Lead Sponsor:
Gan and Lee Pharmaceuticals Gan and Lee Pharmaceuticals, USA